Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice

Incretin therapy has emerged as one of the most popular medications for type 2 diabetes. We have previously reported that the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin attenuates neointima formation after vascular injury in non-diabetic mice. In the present study, we examined whether comb...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Hiroyuki, Nomiyama, Takashi, Terawaki, Yuichi, Horikawa, Takeshi, Kawanami, Takako, Hamaguchi, Yuriko, Tanaka, Tomoko, Motonaga, Ryoko, Fukuda, Takashi, Tanabe, Makito, Yanase, Toshihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477163/
https://www.ncbi.nlm.nih.gov/pubmed/31032431
http://dx.doi.org/10.1016/j.bbrep.2019.100640

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477163/
https://www.ncbi.nlm.nih.gov/pubmed/31032431
http://dx.doi.org/10.1016/j.bbrep.2019.100640

Ejemplares similares